Palatin Technologies, Inc. — Form 10-Q Summary
Reporting period: The filing covers the unaudited quarter and nine months ended March 31, 2013 (Palatin’s fiscal third quarter of 2013). This differs from the request metadata’s “2012 Q3.” Palatin is a development-stage biopharmaceutical company; it reported minimal collaboration revenue and continued operating losses.
Key financial results
| Metric | Three months ended March 31, 2013 | Nine months ended March 31, 2013 |
|---|---|---|
| Revenue | $0 | $10,361 |
| Research and development expense | $2.94 million | $7.73 million |
| General and administrative expense | $1.08 million | $3.14 million |
| Operating loss | $4.02 million | $10.87 million |
| Net loss | $4.02 million | $16.14 million |
| Basic and diluted loss per share | $0.04 | $0.17 |
- Revenue was entirely from AstraZeneca reimbursements; Palatin recognized $10,361 for the nine-month period, versus $62,705 in the prior-year period. With negligible revenue, operating margins are not meaningfully comparable.
- Cash, cash equivalents and short-term investments totaled $29.5 million at March 31, 2013, compared with cash and cash equivalents of $3.8 million at June 30, 2012. Current assets were $30.0 million and current liabilities $2.7 million.
- Operating cash use was $8.6 million for the nine months, versus $10.1 million a year earlier. Financing provided $34.4 million, primarily from a July 2012 private placement; investing used $6.1 million, mostly for short-term investments.
- Total liabilities were $2.8 million. Capital lease obligations totaled about $25,600; the filing reports no material debt financing.
- Accumulated deficit was $255.4 million. The filing states that a significant loss is expected for fiscal 2013.
Changes versus the prior comparable period
- Quarterly net loss narrowed from $6.02 million to $4.02 million; nine-month net loss increased from $12.00 million to $16.14 million.
- Operating expenses declined: nine-month R&D fell to $7.73 million from $9.68 million, and G&A to $3.14 million from $3.47 million. Management attributed lower R&D partly to completion of the bremelanotide Phase 2B trial and reduced staffing and laboratory operations.
- The nine-month loss included a $7.07 million non-operating expense from the increase in fair value of Series B warrants before their reclassification to equity after stockholder approval of additional authorized shares. A $1.75 million tax benefit from sale of New Jersey NOL carryforwards partly offset the loss.
- The July 2012 private placement generated $35.0 million gross and $34.4 million net proceeds. It included warrants to purchase up to approximately 67.5 million shares at $0.01 per share, subject to terms and limitations described in the filing.
Outlook, risks and other notable items
- Palatin reported positive top-line Phase 2B results for bremelanotide for female sexual dysfunction, including statistical significance on the primary and key secondary endpoints. Management said the treatment was generally well tolerated; common adverse events included flushing, nausea and vomiting.
- After an end-of-Phase 2 meeting, management reported preliminary agreement with the FDA on key elements of pivotal Phase 3 studies. It planned to complete protocols and begin patient screening later in 2013. The filing does not provide a clear full Phase 3 budget or financing plan.
- Management believed existing resources could fund planned operations, including preparation for and initiation of Phase 3, through at least calendar 2013. It also stated that current resources would not fund all trials needed for product approval and that Phase 3 would require significant additional capital. Additional financing may be unavailable or unfavorable; without it, Palatin may curtail trials, seek partners earlier, or relinquish rights.
- Other development priorities included PL-3994 and peptide programs for dermatologic, inflammatory and sexual dysfunction indications. AstraZeneca held development and commercialization responsibility for its licensed obesity and diabetes program; Palatin remained eligible for milestone payments and royalties.
- The company had no legal proceedings reported and stated there were no material changes to previously disclosed risk factors. Management concluded disclosure controls were effective as of March 31, 2013.
Important facts for investors to verify
- Confirm the actual reporting period: the filing is for the quarter ended March 31, 2013, not 2012 Q3.
- Review the FDA’s final requirements, timing, design and expected cost for bremelanotide Phase 3, and whether the company secured adequate funding.
- Assess financing and dilution risk from the private-placement warrants and other potential equity or debt issuance. The reported weighted-average share count includes certain nominal-price warrants, so reconcile it with basic shares outstanding.
- Evaluate the sustainability of the cash runway against development spending, collaboration receipts and the company’s stated need for additional capital.
- Review bremelanotide’s full safety and efficacy data and subsequent regulatory and clinical developments; the filing’s results are top-line Phase 2B findings.